The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.
AffiliationCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.
MetadataShow full item record
AbstractIn the criteria used for assessment of response to treatment for advanced breast cancer the definition of no change (NC) is clear; however, there is no indication of the duration of stabilization required for patients to qualify for this category of response. We have made the assumption that NC is a worthwhile category of response if the overall time to progression (TTP) and survival of this group is not significantly different from patients with partial remissions (PR). Two hundred and sixty-three evaluable patients treated with endocrine therapy and 302 evaluable chemotherapy-treated patients were studied and the TTP and survival curves for PR and periods of NC from 1 to 6 months compared. For the endocrine-treated patients the TTP and survival curves for NC became non-significantly different from the PR curves after 4 and 5 months respectively. For chemotherapy-treated patients the TTP curves became non-significantly different from PR at 4 months and for survival the period was 3 months. In order to define NC as a useful category of response and to eliminate the possibility that NC taken for a shorter period could simply represent a slowly progressive tumour, we suggest that the minimum period of disease stabilization be taken as 5 months for both endocrine- and chemotherapy-treated patients.
CitationThe definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. 1988, 24 (10):1567-72 Eur J Cancer Clin Oncol
JournalEuropean Journal of Cancer & Clinical Oncology
- What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
- Authors: Thewes B, Meiser B, Duric VM, Stockler MR, Taylor A, Stuart-Harris R, Links M, Wilcken N, McLachlan SA, Phillips KA, Beith J, Boyle F, Friedlander ML
- Issue date: 2005 Aug
- [A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer].
- Authors: Tashiro H, Nomura Y, Hisamatsu K
- Issue date: 1990 Dec
- Results of endocrine therapy do not predict response to chemotherapy in advanced breast cancer.
- Authors: Steiner R, Stewart JF, Rubens RD
- Issue date: 1983 Nov
- [Progress in breast cancer chemo-endocrine therapy from the survival standpoint].
- Authors: Nomura Y
- Issue date: 1995 May
- Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen.
- Authors: Mouridsen HT, Rose C, Engelsmann E, Sylvester R, Rotmensz N
- Issue date: 1985 Dec